News

Lock In The 81.5% Run - Initiating Verve With A Sell
Verve Therapeutics remains an early-stage biotech, making the rally purely acquisition-driven, not based on fundamentals.
Lilly to buy gene-editing partner Verve for up to $1.3 billion in cardiac care push
Eli Lilly will acquire gene-editing startup Verve Therapeutics for up to $1.3 billion, the companies said on Tuesday, to ...
Eli Lilly's $1.3 Billion Verve Deal Signals Confidence In Gene Editing Space: Analyst
Lilly's Verve acquisition lifts sentiment in gene editing stocks, with analysts calling it a strategic and timely move in a tough funding climate.
Verve Therapeutics downgraded to Hold from Buy at Canaccord
Canaccord downgraded Verve Therapeutics (VERV) to Hold from Buy with a price target of $13, down from $39, after Eli Lilly (LLY) announced a definitive agreement to acquire Verve. Lilly will commence ...
PMLive10h
Eli Lilly to expand cardiovascular disease pipeline with $1.3bn Verve acquisition
Eli Lilly has announced that it will be acquiring Verve Therapeutics in a deal worth approximately $1.3bn, marking a ...
uDiscoverMusic12d
The Verve’s ‘Urban Hymns’ Is Returning To Vinyl
The Verve’s founder and lead singer, Richard Ashcroft, became a solo act in 2000. He recently released the single “Lover,” ...